Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Irene SantiHeleen VellekoopMatthijs M VersteeghSimone A HuygensWinand N M DinjensMaureen Rutten-van MölkenPublished in: Molecular diagnosis & therapy (2024)
NTRK+ patients may have an increased risk of death compared with NTRK- patients. When using historic control data to assess the comparative effectiveness of TRK inhibitors, the prognostic value of the NTRK fusion biomarker should therefore be accounted for.